Posaconazole Prophylaxis in Experimental Systemic Zygomycosis
- 1 January 2007
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (1) , 73-77
- https://doi.org/10.1128/aac.00969-06
Abstract
Three isolates of zygomycetes belonging to two different genera (Rhizopus oryzae and Absidia corymbifera) were used to produce a systemic infection in neutropenic mice. On days -2 and -1 and at 2 h prior to infection, the mice received either posaconazole (POS) at doses ranging from 20 to 80 mg/kg of body weight/day or amphotericin B (AMB) at 1 mg/kg/day. Antifungal drug efficacy was assessed by determination of the prolongation of survival, determination of the percentage of infected organs (brain, lung, spleen, and kidney), and histological examination for the number of infection foci and their sizes in brain and kidney tissues. AMB significantly prolonged the survival of mice infected with all isolates. POS significantly prolonged the survival of mice infected with zygomycetes. Cultured organs from mice infected with R. oryzae were all positive, while treated mice challenged with A. corymbifera generally showed lower percentages of infected organs compared with the percentages for the controls. Zygomycete isolates established an active infection (the presence of hyphae) in the brains and the kidneys of all controls. In mice challenged with R. oryzae, both antifungal drugs were effective at reducing the number and the size of infection foci in the kidneys. Only AMB reduced the numbers, but not the sizes, of infection foci in the brain. Finally, both drugs significantly reduced the numbers and the sizes of infection foci in both tissues of mice infected with A. corymbifera. Our data suggest that prophylaxis with POS has some potential to prevent zygomycosis.Keywords
This publication has 15 references indexed in Scilit:
- Safety of Long-Term Oral Posaconazole Use in the Treatment of Refractory Invasive Fungal InfectionsClinical Infectious Diseases, 2006
- Posaconazole Is Effective as Salvage Therapy in Zygomycosis: A Retrospective Summary of 91 CasesClinical Infectious Diseases, 2006
- Human Recombinant Antimannan Immunoglobulin G1 Antibody Confers Resistance to Hematogenously Disseminated Candidiasis in MiceInfection and Immunity, 2006
- Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported CasesClinical Infectious Diseases, 2005
- Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and ManagementClinical Microbiology Reviews, 2005
- Caspofungin Inhibits Rhizopus oryzae 1,3-β- d -Glucan Synthase, Lowers Burden in Brain Measured by Quantitative PCR, and Improves Survival at a Low but Not a High Dose during Murine Disseminated ZygomycosisAntimicrobial Agents and Chemotherapy, 2005
- PosaconazoleDrugs, 2005
- Zygomycosis: Reemergence of an Old PathogenClinical Infectious Diseases, 2004
- Activity of Posaconazole in Treatment of Experimental Disseminated ZygomycosisAntimicrobial Agents and Chemotherapy, 2003
- FACTORS DETERMINING THE SUSCEPTIBILITY OF MICE TO EXPERIMENTAL PHYCOMYCOSISJournal of Medical Microbiology, 1975